Categories AlphaGraphs, Earnings, Technology
Accenture earnings preview: Wall St sees broad-based growth in Q1
Management consulting firm Accenture (ACN) is reporting first-quarter results on Thursday, December 20, before the opening bell. Wall Street expects to see broad-based growth across all segments and throughout operating regions due to higher demand for its products and services.
Total revenue is expected to jump 10% to $10.43 billion, while earnings per share is projected to grow 2.8% to $1.84 during the first quarter.
Analysts predict that revenues from all the segments would improve during this period, with the highest growth expected in the Communications, Media & Technology unit as well as the Products unit. Meanwhile, the Financial Services segment is expected to record the slowest growth during the first quarter.
The Dublin-headquartered company has a history of beating earnings estimates. During the prior sequential quarter, the company reported earnings of $1.58 per share, surpassing the Street consensus by 3 cents. Meanwhile, revenue of $10.1 billion was broadly in line with Wall Street estimates.
Accenture shares are trading almost flat since the start of this year. In the trailing 52-week period, the stock is up a modest 0.8%.
It’s time for Accenture to reap the dividends of digital push
On the other hand, analysts continue to stay bullish on the stock with an average rating of Moderate Buy. Ten out of 16 analysts covering the stock recommend Buy rating. ACN has an average 12-month price target of $185.38, which is at a 21% upside from its close on Monday.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company